MiR-185-5p regulated processes like epithelial–mesenchymal transition (EMT) and invasion of breast cancer cells by targeting the receptor for advanced glycation end-products (RAGE) [40], while miR-143-3p inhibits RAS/MEK/ERK and PI3K/AKT/mTOR pathways, which are significant in HER2 downstream signaling [41]. Here, AGER is linked to breast cancer.